FDA Current Good Manufacturing Practice regulation governing finished pharmaceutical products — inspection system design, calibration, and records must comply with Subpart J (Laboratory Controls) and Subpart K (Records and Reports)

FDA Electronic Records regulation requiring that all inspection data, batch records, and calibration logs generated by computerized inspection systems be authenticated, time-stamped, and protected against alteration

United States Pharmacopeia injection quality standards require particle inspection for injectable pharmaceuticals — X-ray inspection complements visual inspection for opaque containers and particulate matter in liquid products

EU GMP Annex 11 (Computerized Systems) and Annex 1 (Manufacture of Sterile Medicinal Products) impose additional validation and electronic record requirements for pharmaceutical inspection systems in EU-regulated markets

Solid Oral Dosage (Tablets and Capsules)

Bottle and blister pack inspection for solid oral dosage products verifies tablet count, detects broken or missing tablets, identifies foreign particles, and measures fill level. X-ray inspection on high-speed bottling lines (100-600 bottles per minute) must maintain count accuracy above 99.99% while generating per-bottle inspection records for batch documentation. AI models trained on tablet density profiles detect chipped, cracked, and discolored tablets that indicate API content deviation.

Parenteral and Injectable Products

Vials, ampoules, and prefilled syringes require X-ray inspection for fill volume verification, particulate detection in liquid product, container closure integrity, and stopper or plunger seating confirmation. Particulate matter requirements for injectables are among the most stringent in pharmaceutical quality — X-ray complements visual inspection by detecting particles in opaque or amber containers where optical inspection is unreliable.

Blister Pack Inspection

Blister packs present unique inspection challenges — X-ray must verify that each cavity contains the correct tablet or capsule, detect empty pockets, identify broken or partial tablets through the forming film, and confirm seal integrity across the full blister width. High-speed blister packaging at 200-400 packs per minute requires X-ray systems with frame acquisition rates and AI classification speed matched to the line throughput with less than 5ms inspection window per blister cavity.

IV Bags and Flexible Containers

Intravenous solution bags and flexible pharmaceutical containers require X-ray inspection for fill volume, particulate matter, port integrity, and overwrap seal quality. The low density of IV solution requires high-sensitivity X-ray calibration to detect small particulates. 2M Technology configures IV bag inspection systems with beam energy and detector sensitivity optimized for the specific solution density and container material of each product line.

Is pharmaceutical X-ray inspection required by FDA?

FDA 21 CFR Part 211 requires pharmaceutical manufacturers to have laboratory controls that include inspection and testing of drug products to ensure they meet established specifications. While X-ray inspection is not explicitly mandated by name, it is the primary method for meeting tablet count, fill level, and foreign particle specifications at commercial production line speeds. FDA Warning Letters have cited failures in finished product inspection as GMP violations — X-ray inspection with validated calibration and electronic records is the GMP-compliant approach. For injectable products, USP particle requirements make X-ray inspection for opaque containers a practical necessity.

What validation documentation is required for a pharma X-ray inspection system?

Pharmaceutical X-ray inspection systems require validation under GAMP 5 Category 4 (Configured Products) or Category 5 (Custom Software) depending on the AI configuration complexity. Required documentation includes: User Requirements Specification (URS), Functional Requirements Specification (FRS), Installation Qualification (IQ) confirming the system is installed per design, Operational Qualification (OQ) confirming all functions operate within specification, and Performance Qualification (PQ) demonstrating the system performs correctly under production conditions. 21 CFR Part 11 compliance requires separate validation of the electronic records and audit trail functionality. 2M Technology provides IQ/OQ documentation packages for all deployed pharmaceutical inspection systems.

How does X-ray inspection verify tablet count without opening the bottle?

X-ray imaging penetrates the sealed bottle or blister packaging and creates a density image of the contents. AI algorithms analyze this image to count individual tablets or capsules by detecting each discrete density object within the container. For standard round tablets in clear or amber HDPE bottles, count accuracy exceeds 99.99% at production speeds. For irregular tablet shapes, multi-layer tablets, or tablets of similar size and shape, AI models are trained on product-specific image libraries to maintain count accuracy. 2M Technology validates count accuracy against manual count reference for each new product configuration before production deployment.

What happens when a pharmaceutical X-ray inspection system detects a defect?

When the inspection system detects a non-conforming unit, it triggers the reject mechanism (air blast, pusher, or diverter gate) to remove the unit from the production stream within milliseconds of detection. The rejection event is logged with timestamp, lot number, rejection reason, and an archived X-ray image of the rejected unit. If the reject rate exceeds a defined threshold within a sampling window, the system triggers a line hold alarm requiring supervisor intervention and CAPA documentation before production continues. All rejection data is available for batch record inclusion and statistical process control trending.